ZDHHC5 biomarker_for lung adenocarcinoma
Evidence from:
primary |
all sources
Evidence (7 sources)
Potential Role of S-Palmitoylation in Cancer Stem Cells of Lung Adenocarcinoma.
(2021)
PMID:34621750
cited
12 ZDHHCs were significantly upregulated in LUAD (fold change > 1, P < 0.05); ZDHHC5 was highlighted as differentially expressed.
confidence: 0.94
Potential Role of S-Palmitoylation in Cancer Stem Cells of Lung Adenocarcinoma.
(2021)
PMID:34621750
cited
identification of the prognostic value of ZDHHC5 in LUAD
confidence: 0.95
Potential Role of S-Palmitoylation in Cancer Stem Cells of Lung Adenocarcinoma.
(2021)
PMID:34621750
cited
ZDHHC5 as a key PAT in LUAD for its over-expression and malignant prognosis in LUAD patients
confidence: 0.95
Potential Role of S-Palmitoylation in Cancer Stem Cells of Lung Adenocarcinoma.
(2021)
PMID:34621750
cited
ZDHHC5 was the only gene with prognostic value.
confidence: 0.97
Potential Role of S-Palmitoylation in Cancer Stem Cells of Lung Adenocarcinoma.
(2021)
PMID:34621750
cited
ZDHHC5 was overexpressed in LUAD patients, which was based on large sample size.
confidence: 0.95
Potential Role of S-Palmitoylation in Cancer Stem Cells of Lung Adenocarcinoma.
(2021)
PMID:34621750
cited
LCE was employed to evaluate the prognostic value of ZDHHC5 ...
confidence: 0.96
Potential Role of S-Palmitoylation in Cancer Stem Cells of Lung Adenocarcinoma.
(2021)
PMID:34621750
cited
HR of ZDHHC5 corrected by meta-analysis was 1.19 (P < 0.01), which indicated ZDHHC5 was associated with an unfavorable prognosis in LUAD.
confidence: 0.96